Home > Cardiology > ESC 2022 > High-dose influenza vaccine: mortality benefit?

High-dose influenza vaccine: mortality benefit?

Presented By
Dr Niklas Dyrby Johansen, Herlev and Gentofte Hospital, Denmark
Conference
ESC 2022
Trial
Phase 2, DANFLU-1
Findings from a pragmatic randomised Danish trial showed that high-dose influenza vaccination (60 μg of haemagglutinin antigen) in older adults reduced the risk of death by 49%, as well as reduced hospitalisation for influenza or pneumonia by 64%, compared with standard-dose influenza vaccination (15 μg of haemagglutinin antigen). Dr Niklas Dyrby Johansen (Herlev and Gentofte Hospital, Denmark) pointed out that several previous studies have indicated that influenza infection is strongly associated with heart failure and myocardial infarction hospitalisations, coupled with evidence that influenza vaccination can prevent cardiovascular events [1–3]. The DANFLU-1 study (NCT05048589) aimed to address the unmet need that to date, no randomised trial has assessed the effects of high-dose, compared with standard-dose, quadrivalent influenza vaccines on severe clinical ou...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on